A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy - Trial NCT06240598
Access comprehensive clinical trial information for NCT06240598 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Ovarian Cancer. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Memorial Sloan Kettering Cancer Center
Timeline & Enrollment
Phase 2
Jan 26, 2024
Jan 01, 2026
Primary Outcome
minimal residual disease (MRD) status
Summary
The researchers are doing this study to look at the health outcomes of people with advanced
 ovarian cancer who have a second look laparoscopy (SLL) after they complete their first
 course of chemotherapy. The researchers will compare the health outcomes of people who have
 minimal residual disease (MRD-small amounts of cancer cells in the body after a person
 receives treatment) at the time of SLL with the health outcomes of people who do not have MRD
 at the time of SLL. The researchers are also doing this study to determine if SLL is safe and
 practical (feasible) in people with advanced ovarian cancer who have completed the first
 course of therapy for their disease.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06240598
Non-Device Trial